Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc. (THRX) priced its initial public offering on Oct 7, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $160M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $600.5M. Jefferies was lead-left underwriter, joined by Leerink Partners, Cantor and Wedbush. Gunderson Dettmer advised the company and WilmerHale advised the underwriters.

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted cancer therapies that address drug resistance mutations in key driver oncogenes. Its initial focus is a next generation of tyrosine kinase inhibitors.

Status

IPO

Ticker

THRX

Exchange

Nasdaq Global Select

Priced

Oct 7, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$160M

Market cap at IPO price

$600.5M

First filed

Sep 15, 2021

Underwriters

Jefferies, Leerink Partners, Cantor and Wedbush

Company counsel

Gunderson Dettmer

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.